Sotera Health Co (SHC)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.74B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sotera Health Co (SHC) Earnings: Report Dates and Results
Sotera Health (SHC) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Sotera Health reported EPS of $0.27, above the $0.24 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SHC has an expected report date of Feb 22, 2027.
SHC Earnings Call
The latest SHC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, SHC beat 21, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $324.89M, up 4.4% from $311.31M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.27 | $0.24 | N/A | +12.50% | Beat | +3.8% | 10 | 1 up, 0 down | Nov 3, 2026 | $324.89M |
| Jun 30, 2026 | $0.24 | $0.22 | N/A | +9.09% | Beat | +20.0% | 10 | 0 up, 2 down | Aug 6, 2026 | $321.38M |
| Mar 31, 2026 | $0.18 | $0.17 | $0.15 - $0.18 | +5.88% | Beat | +28.6% | 10 | 0 up, 1 down | May 5, 2026 | $280.05M |
| Dec 31, 2025 | $0.26 | $0.24 | $0.24 - $0.25 | +7.35% | Beat | +23.8% | 10 | 6 up, 0 down | Feb 24, 2026 | $303.44M |
| Sep 30, 2025 | $0.26 | $0.22 | $0.21 - $0.22 | +18.18% | Beat | +52.9% | 7 | 1 up, 0 down | Nov 4, 2025 | $311.31M |
| Jun 30, 2025 | $0.20 | $0.17 | $0.17 - $0.18 | +17.65% | Beat | +5.3% | 7 | 0 up, 8 down | Aug 8, 2025 | $294.34M |
| Mar 31, 2025 | $0.14 | $0.12 | $0.11 - $0.13 | +16.67% | Beat | +7.7% | 8 | 0 up, 1 down | May 1, 2025 | $254.52M |
| Dec 31, 2024 | $0.21 | $0.20 | $0.19 - $0.21 | +4.01% | Beat | -19.2% | 8 | 1 up, 1 down | Feb 27, 2025 | $290.20M |
| Sep 30, 2024 | $0.17 | $0.18 | $0.18 - $0.19 | -5.56% | Miss | -19.0% | 8 | 1 up, 0 down | Nov 5, 2024 | $285.47M |
| Jun 30, 2024 | $0.19 | $0.16 | $0.16 - $0.17 | +18.75% | Beat | -9.5% | 8 | 0 up, 0 down | Aug 5, 2024 | $276.59M |
| Mar 31, 2024 | $0.13 | $0.12 | $0.11 - $0.15 | +8.33% | Beat | 0.0% | 7 | 0 up, 1 down | May 2, 2024 | $248.18M |
| Dec 31, 2023 | $0.26 | $0.26 | $0.24 - $0.28 | 0.00% | In line | +4.0% | 7 | 1 up, 0 down | Feb 27, 2024 | $310.24M |
| Sep 30, 2023 | $0.21 | $0.20 | $0.18 - $0.21 | +5.00% | Beat | -8.7% | 6 | 0 up, 0 down | Nov 1, 2023 | $263.18M |
| Jun 30, 2023 | $0.21 | $0.17 | $0.16 - $0.19 | +23.53% | Beat | -22.2% | 7 | 0 up, 0 down | Aug 3, 2023 | $255.28M |
| Mar 31, 2023 | $0.13 | $0.14 | $0.13 - $0.14 | -7.14% | Miss | -40.9% | 7 | 0 up, 0 down | May 3, 2023 | $220.59M |
| Dec 31, 2022 | $0.25 | $0.22 | $0.21 - $0.23 | +13.64% | Beat | +8.7% | 7 | 0 up, 0 down | Feb 28, 2023 | N/A |
| Sep 30, 2022 | $0.23 | $0.22 | $0.21 - $0.23 | +4.55% | Beat | +9.5% | 8 | 0 up, 0 down | Nov 2, 2022 | $248.70M |
| Jun 30, 2022 | $0.27 | $0.24 | $0.23 - $0.25 | +12.50% | Beat | +3.8% | 8 | 0 up, 0 down | Aug 4, 2022 | $266.64M |
| Mar 31, 2022 | $0.22 | $0.20 | $0.18 - $0.20 | +10.00% | Beat | +22.2% | 8 | 0 up, 0 down | May 5, 2022 | $236.75M |
| Dec 31, 2021 | $0.23 | $0.22 | $0.21 - $0.23 | +4.55% | Beat | +155.6% | 9 | N/A | Mar 1, 2022 | $241.25M |
| Sep 30, 2021 | $0.21 | $0.20 | $0.20 - $0.21 | +5.00% | Beat | +950.0% | 9 | N/A | Nov 10, 2021 | $226.16M |
| Jun 30, 2021 | $0.26 | $0.21 | $0.20 - $0.22 | +23.81% | Beat | N/A | 9 | N/A | Aug 12, 2021 | $251.92M |
| Mar 31, 2021 | $0.18 | $0.16 | $0.15 - $0.17 | +12.50% | Beat | +1551.4% | 9 | N/A | May 13, 2021 | $212.15M |
| Dec 31, 2020 | $0.09 | $0.07 | $0.06 - $0.09 | +28.57% | Beat | +725.7% | 8 | N/A | Mar 9, 2021 | $216.84M |
| Sep 30, 2020 | $0.02 | $0.08 | N/A | -75.00% | Miss | N/A | N/A | N/A | Nov 19, 2020 | $200.03M |
| Jun 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Sep 30, 2020 | $213.09M |
| Mar 31, 2020 | $0.01 | N/A | N/A | N/A | N/A | -60.1% | N/A | N/A | Jun 29, 2020 | $188.20M |
| Dec 31, 2019 | $0.01 | N/A | N/A | N/A | N/A | -60.1% | N/A | N/A | Mar 31, 2020 | $193.49M |
| Jun 30, 2019 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $194.76M |
| Mar 31, 2019 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $194.76M |
| Dec 31, 2018 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.86, up 22.9% from the year before. It was $0.03 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.86 | +22.9% |
| Dec 31, 2024 | $0.70 | -13.6% |
| Dec 31, 2023 | $0.81 | -16.5% |
| Dec 31, 2022 | $0.97 | +10.2% |
| Dec 31, 2021 | $0.88 | +627.9% |
| Dec 31, 2020 | $0.12 | +763.6% |
| Dec 31, 2019 | $0.01 | N/A |
| Dec 31, 2018 | $0.03 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,528 | 13 | |
| 2026Q2 | Jun 30, 2026 | 7,570 | 15 | |
| 2026Q1 | Mar 31, 2026 | 5,093 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,294 | 14 | |
| 2025Q3 | Sep 30, 2025 | 4,826 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,561 | 11 | |
| 2025Q1 | Mar 31, 2025 | 5,939 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,346 | 13 |
2026Q3 Earnings Call
Opening remarks
Jason Peterson Vice President of Investor Relations Good morning, and welcome to Sotera Health's third quarter earnings call. Today's press release and earnings presentation are available on the Investors section of our website at soterahealth.com. This webcast is being recorded, and a replay will also be available on the Investors section of the Sotera Health website shortly after the call. Joining me today are Chief Executive Officer Alton E. Shader, Chief Financial Officer Jonathan Lyons, and Executive Chairman Michael Petras. During today's call, some of our comments may be considered forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to Sotera Health's SEC filings and the forward-looking statements slide at the beginning of the earnings presentation for a description of these risks and uncertainties. The company assumes no obligation to update any such forward-looking statements. Please note that during the discussion today, the company will present both GAAP and non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, tax rate applicable to adjusted net income, adjusted net income, adjusted EPS, net debt, and net leverage ratio, as well as constant-currency comparisons. A reconciliation of GAAP to non-GAAP measures for all relevant periods may be found in the schedules attached to the company's press release and in the supplemental slides to the earnings presentation. The operator will be assisting with the Q&A portion of the call today. Please limit yourself to one question and one follow-up. For further questions, feel free to reach out to the Investor Relations team. I will now turn the call over to Sotera Health CEO, Alton E. Shader.
Alton E. Shader CEO Good morning, and thank you for joining us. Today, we reported solid top- and bottom-line growth versus the third quarter of 2025, driven by strong execution and sequential adjusted EBITDA margin improvement of nearly 100 basis points. For the third quarter, we delivered constant-currency revenue growth of 4.4% and constant-currency adjusted EBITDA growth of 4% versus the same period last year. Sterigenics continued to perform well, generating 8.2% constant-currency revenue growth and 57 basis points of segment income margin expansion, despite experiencing some softness in the medical device market during the quarter, which has continued into the early part of Q4. Nelson Labs delivered another strong quarter, with revenue increasing 9.2% on a constant-currency basis as the team continued to execute on complex projects to support our customers' regulatory needs. As expected, Nordion results reflected the timing of cobalt-60 harvest schedules. The Nordion teams did a great job delivering critical cobalt-60 shipments for their customers and expanded segment income margins by 71 basis points.
Frequently Asked Questions About SHC
When is Sotera Health's next earnings date?
Sotera Health's next earnings report is expected for Feb 22, 2027.
Did SHC beat earnings estimates last quarter?
Yes. Sotera Health reported EPS of $0.27 for the quarter ended Sep 30, 2026, above the $0.24 estimate, a 12.50% surprise.
What EPS do analysts expect from SHC next quarter?
The consensus EPS estimate for Sotera Health for the quarter ending Dec 31, 2026 is $0.26 from 11 analysts, with estimates from $0.25 to $0.28.
How often does SHC beat earnings estimates?
Sotera Health beat the EPS estimate in each of the last 8 quarters, with an average surprise of +11.42%.
SHC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors